Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions: Eculizumab, Placebo; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 19
States / cities: Scottsdale, Arizona • Carlsbad, California • Washington D.C., District of Columbia + 15 more

Conditions: Primary Immune Thrombocytopenia
Interventions: PF-06835375; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Greenville, North Carolina

Conditions: Multiple Sclerosis
Interventions: Resilience-Based Program for Support Partners of PwMS; Behavioral
Lead sponsor: Healios Inc.; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Flemington, New Jersey

Conditions: Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions: Sitaxsentan, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 32
States / cities: Fountain Valley, California • Mather, California • Sacramento, California + 28 more

Conditions: Shy-Drager Syndrome, Multiple System Atrophy
Interventions: Pseudoephedrine + 480 ml water, Pseudoephedrine + 50 ml water, Placebo + 480 ml water (optional), Placebo + 50 ml water (optional); Drug · Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Acquired Bleeding Disorder, Intracerebral Haemorrhage
Interventions: eptacog alfa (activated); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 829 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 77
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more

Conditions: Progressive Keratoconus
Interventions: Test Article A, Test Article B, Placebo, KXL medical device system; Drug · Device
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 12 Years to 55 Years
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Heart Failure, Cardiotoxicity, Cardiac Toxicity, Antineoplastics Toxicity, Cancer
Interventions: Stopping Heart Failure Medication(s); Other
Lead sponsor: Dinesh Thavendiranathan; Other
Eligibility: 18 Years and older
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 2
States / cities: Los Angeles, California • Boston, Massachusetts

Conditions: Pertussis, Tetanus, Diphtheria
Interventions: ADACEL®:Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed, BOOSTRIX®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 11 Years to 18 Years
Enrollment: 647 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 10
States / cities: Annapolis, Maryland • Baltimore, Maryland • Frederick, Maryland + 6 more

Conditions: Hepatitis C
Interventions: 200 mg INX-08189 Fasted, Placebo QD Fasted, 100 mg INX-08189 QD, Placebo QD, 100 mg INX-08189 with low-fat meal, Placebo with low-fat meal, 100 mg INX-08189 BID Fasted, Placebo BID Fasted, ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: cisplatin, paclitaxel, phenoxodiol; Drug
Lead sponsor: MEI Pharma, Inc.; Industry
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions: Trifluridine; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: New York, New York

Conditions: Solid Tumors
Interventions: E7080, Comparator Drug, Comparator Drug: Sorafenib; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 3
States / cities: Torrance, California • Chicago, Illinois • Detroit, Michigan

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: Creatine Monohydrate; Drug
Lead sponsor: The Avicena Group; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 8
States / cities: San Francisco, California • Kansas City, Kansas • Albuquerque, New Mexico + 5 more

Conditions: Major Depressive Disorder
Interventions: apimostinel, Placebo; Drug
Lead sponsor: Syndeio Biosciences, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Rogers, Arkansas

Conditions: Pain, Nausea, Vomiting
Interventions: CL-108; Drug
Lead sponsor: Charleston Laboratories, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Physical Disability
Interventions: EnhanceWellness for Disability (EW-D), Wellness Education; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 45 Years to 64 Years
Enrollment: 516 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Carcinoma of the Appendix, Primary Peritoneal Cavity Cancer
Interventions: mitomycin C, oxaliplatin, therapeutic conventional surgery, quality-of-life assessment, hyperthermic intraperitoneal chemotherapy; Drug · Procedure · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 3
States / cities: Winston-Salem, North Carolina • Pittsburgh, Pennsylvania • Houston, Texas

Conditions: Atopic Dermatitis
Interventions: 0417, Vehicle of 0417 test product, Tacrolimus Ointment 0.03%; Drug
Lead sponsor: Fougera Pharmaceuticals Inc.; Industry
Eligibility: 8 Years and older
Enrollment: 899 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Melville, New York

Conditions: Oral Mucositis, Head and Neck Cancer
Interventions: EN3285, Placebo, Standard of care; Drug · Other
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Louisville, Kentucky • Houston, Texas

Conditions: Breast Cancer, Diagnostic Imaging
Interventions: Gadobutrol (Gadavist, Gadovist, BAY86-4875); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 7
States / cities: La Jolla, California • Los Angeles, California • Newport Beach, California + 4 more

Conditions: Soft Tissue Infections
Interventions: Standard care, beta-lactam; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 8
States / cities: Birmingham, Alabama • Mobile, Alabama • Melbourne, Florida + 4 more

Conditions: Obstructive Hypertrophic Cardiomyopathy (oHCM)
Interventions: Aficamten (5 mg, 10 mg, 15 mg, and 20 mg), Placebo to match aficamten; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 48
States / cities: Anchorage, Alaska • La Jolla, California • Los Angeles, California + 39 more

Conditions: Primary Hypercholesterolemia, Mixed Dyslipidemia
Interventions: Evolocumab Pre-filled Syringe, Evolocumab AI/pen; Biological
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 21
States / cities: Encino, California • Thousand Oaks, California • Ventura, California + 17 more

Search by objective public record fields.

A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)

Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

Resilience-Based Program for Support Partners of Persons With Multiple Sclerosis

Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)

Water and Sudafed in Autonomic Failure

Recombinant Factor VIIa in Acute Intracerebral Haemorrhage

Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus

The STOP-MED CTRCD Trial

Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®

Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve Subjects

Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Evaluation of the Therapeutic Benefit of r-metHuIFN- Gamma in AIDS Patients With Disseminated Mycobacterium Avium-Intracellulare (MAI) Infection: A Multi-Centered Pilot Study

Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials

Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis

Multiple Ascending Dose and Electroencephalography Trial of GATE-202 in Healthy Volunteers

A Multi-Center Actual-Use Study on the Safety of CL 108 for the Treatment of Moderate to Severe Acute Pain Associated With Osteoarthritis of the Knee or Hip

A Community Wellness Program for Adults Living With Long-term Physical Disability

Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Tumors of the Appendix

Study of 0417 Ointment in the Treatment of Atopic Dermatitis

EN3285 for the Prevention or Delay of Oral Mucositis in Patients With Head and Neck Cancer

Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI

A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM

Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen